Equitable Holdings Inc. purchased a new stake in shares of Repligen Corporation (NASDAQ:RGEN – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 11,404 shares of the biotechnology company’s stock, valued at approximately $1,556,000.
Several other hedge funds and other institutional investors have also made changes to their positions in RGEN. Measured Wealth Private Client Group LLC acquired a new stake in Repligen in the 3rd quarter valued at approximately $29,000. Los Angeles Capital Management LLC acquired a new position in Repligen during the 4th quarter worth $36,000. Northwestern Mutual Wealth Management Co. acquired a new position in Repligen during the 2nd quarter worth $52,000. Farther Finance Advisors LLC grew its stake in shares of Repligen by 61.8% in the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 128 shares in the last quarter. Finally, Itau Unibanco Holding S.A. grew its stake in shares of Repligen by 38.0% in the fourth quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 104 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
RGEN has been the topic of a number of recent analyst reports. Royal Bank Of Canada began coverage on shares of Repligen in a research note on Thursday, May 14th. They set an “outperform” rating and a $160.00 price objective on the stock. Wells Fargo & Company increased their target price on shares of Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a research report on Thursday, July 30th. Barclays raised their target price on shares of Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Zacks Research upgraded shares of Repligen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Finally, JPMorgan Chase & Co. upped their price target on shares of Repligen from $165.00 to $175.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Repligen has an average rating of “Buy” and a consensus target price of $166.43.
Insider Activity at Repligen
In related news, CFO Jason K. Garland sold 733 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the sale, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at $2,807,055. This represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.60% of the stock is owned by insiders.
Repligen Price Performance
NASDAQ:RGEN opened at $176.27 on Friday. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. The business’s 50-day moving average price is $151.99 and its 200 day moving average price is $133.09. Repligen Corporation has a 52-week low of $100.99 and a 52-week high of $188.73. The firm has a market cap of $9.95 billion, a P/E ratio of 241.47, a PEG ratio of 3.32 and a beta of 1.03.
Repligen (NASDAQ:RGEN – Get Free Report) last issued its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The company had revenue of $204.13 million during the quarter, compared to the consensus estimate of $201.59 million. During the same period in the prior year, the company earned $0.26 EPS. Repligen’s revenue was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, sell-side analysts predict that Repligen Corporation will post 2.06 earnings per share for the current fiscal year.
Repligen Profile
Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.
The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.
Read More
- Five stocks we like better than Repligen
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN – Free Report).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
